PDF(Pubmed)
Abstract：
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 is the virus responsible for the 2019 global pandemic. Pulmonary complications of COVID-19 are well established in the literature. However, the virus causes numerous extrapulmonary manifestations, notably acute aortic occlusion (AAO). COVID-19 creates a hypercoagulable state via the upregulation of numerous procoagulant cytokines in endothelial cells of blood vessels. We present a case of a 63-year-old patient without a previous history of prothrombotic disorders who developed AAO in the distal abdominal aorta and bilateral common iliac arteries after contracting COVID-19. The patient was a poor surgical candidate and was treated with fibrinolytics that were administered via an EkoSonic™ Endovascular System (EKOS) catheter using a bilateral transfemoral approach. This case highlights a unique treatment option for non-surgical candidates with AAO.
摘要：
严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）或COVID-19是导致2019年全球大流行的病毒。COVID-19的肺部并发症在文献中得到了证实。然而,这种病毒会引起许多肺外表现，尤其是急性主动脉闭塞（AAO）。COVID-19通过上调血管内皮细胞中多种促凝血细胞因子而产生高凝状态。我们介绍了一名63岁的患者，该患者先前没有血栓形成前疾病史，该患者在COVID-19收缩后在远端腹主动脉和双侧髂总动脉中出现AAO。该患者是不良的手术候选者，并接受了通过EkoSonic™血管内系统（EKOS）导管使用双侧经股入路给予的纤维蛋白溶解剂治疗。此病例突出了AAO非手术候选人的独特治疗选择。
